Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects

Inclusion Criteria: * Healthy, Caucasian, male subjects aged 18-45 years inclusive. * Weight between 60-100 kg and a BMI within the permitted range for their height using Quetelet's index - weight (kg)/height²(m). The permitted index is between 18-28. * Non-smokers, or ex-smokers that have not smoked for at least 3 months prior to screening. Exclusion Criteria: * Subjects who have history or evidence of hypertrophic or keloid scarring or with tattoos or previous scars in the area to be biopsied. * Afro-Caribbean subjects are excluded because of the increased susceptibility to hypertrophic and keloid scarring. * Subjects who have evidence of any past or present clinically significant disease, particularly coagulation disorders, immuno-mediated conditions and skin diseases and allergies, such as clinically significant eczema. * Subjects with a history of clinically significant allergies, especially drug hypersensitivity to lignocaine or allergy to surgical dressings to be used in this trial. * Subjects with any clinically significant abnormality following review of pre-trial laboratory data and physical examination. * Subjects who are taking, or have taken, certain prescribed or investigational drugs in the three weeks prior to Day 0 and in particular topical or systemic steroids, anti-inflammatory and anti-coagulant drugs. Certain drugs are not excluded in this trial. These include OTC analgesics including paracetamol and codeine, vitamin and mineral supplements and OTC cold remedies. * Subjects who drink more than 28 units of alcohol per week (1 unit = 1/2 pint of beer (285mls) or 25ml of spirits or 1 glass of wine). * Subjects who have evidence of drug abuse. * Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B surface antigen or hepatitis C antibody. Subjects with previous vaccination against Hepatitis B are not excluded per se. * Subjects who are known to have or had serum hepatitis or who are carriers of the hepatitis B core antibody and who show less than 10 units per litre of Anti-HBs. * Subjects who have previously had a positive result to the test for HIV antibodies, or who admit to belonging to a high risk group. * In the opinion of the investigator, a subject who is not likely to complete the trial for what ever reason.